Ceritinib is an FDA approved drug used in treating non-small cell lung cancer was found to have anti-cancer activity and when combined with paclitaxel is more efficient, reveals a new study.
Developing new drugs to treat cancer can be a painstaking process taking over a decade from start to Food and Drug Administration approval. Scientists are trying to develop innovative strategies to identify and test new drugs quicker and more efficiently.
Understanding the Cause and Possible Treatment for a Rare Form of Sarcoma
A potential cause and a promising new treatment for inflammatory myofibroblastic tumor has been discovered by Mayo Clinic researchers.
Advertisement
‘Ceritinib used in treating ALK-rearranged non-small cell lung cancer can also treat other cancers, and when combined with paclitaxel drug can be more effective.’
Tweet it Now
A team of researchers at Moffitt Cancer Center used cellular drug screening, functional proteomics and computer-based modeling to determine whether drugs with well-known targets may be repurposed for use against other biological targets.
The research team found that ceritinib has anti-cancer activity against previously unknown targets. Their results were published in the journal, Nature Chemical Biology.
![New Drug Shows Promise in Rare Lung Cancer]( "New Drug Shows Promise in Rare Lung Cancer")
Ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer (NSCLC), find researchers.
For the past 20 years, there has been an emphasis on targeted cancer therapy targeting a specific driver of cancer development to minimize side effects typically seen with chemotherapy. This personalized approach has been successful in certain types of cancer that are primarily driven by a single DNA alteration, such as found in chronic myeloid leukemia. However, the majority of cancers are not caused by a single mutation; rather, cancer is more commonly caused by a large network of mutations and alterations.
Some researchers, including those from Moffitt, are beginning to rethink the targeted approach to cancer therapy. They believe that developing drugs that act on multiple targets, called a polypharmacology approach, may more effectively treat those cancers that have a network of alterations.
In order to identify drugs that act on multiple targets, Moffitt researchers screened 240 drugs that are either FDA approved or in clinical development. They noticed that the drug ceritinib acts differently than other drugs in its class.
Ceritinib targets a protein called ALK, and is approved to treat patients with ALK-rearranged metastatic non-small cell lung cancer. Their research found that ceritinib also inhibits the growth of lung cancer cells that do not have genetic alterations in the ALK gene.
After an extensive set of experiments to learn how ceritinib worked in cells without ALK rearrangements, they discovered the drug inhibits several other previously unknown targets, and that these signals converge onto a protein known to be responsible for causing drug resistance to paclitaxel.
Importantly, the researchers showed that ceritinib combined with paclitaxel was more effective than either agent alone at reducing cell viability.
These findings suggest that ceritinib together with paclitaxel may be effective against other cancers that do not have ALK rearrangements, and that this drug combination may be used to target a network of changes in cancer.
"The results also demonstrate the benefits of using a combined screening, proteomics and computer-based modeling approach to identify drugs that act on multiple targets and to determine how they function," said study lead author Uwe Rix, Ph.D., assistant member of the Drug Discovery Program at Moffitt.
"In the future, this strategy may facilitate further drug repurposing efforts and lead to an increase in new therapy options for patients with difficult-to-treat diseases."
Source: Eurekalert
New Drug Shows Promise in Rare Lung Cancer
Ceritinib appears to be effective against advanced ALK-positive non-small cell lung cancer (NSCLC), find researchers.
Advertisement
For the past 20 years, there has been an emphasis on targeted cancer therapy targeting a specific driver of cancer development to minimize side effects typically seen with chemotherapy. This personalized approach has been successful in certain types of cancer that are primarily driven by a single DNA alteration, such as found in chronic myeloid leukemia. However, the majority of cancers are not caused by a single mutation; rather, cancer is more commonly caused by a large network of mutations and alterations.
Some researchers, including those from Moffitt, are beginning to rethink the targeted approach to cancer therapy. They believe that developing drugs that act on multiple targets, called a polypharmacology approach, may more effectively treat those cancers that have a network of alterations.
In order to identify drugs that act on multiple targets, Moffitt researchers screened 240 drugs that are either FDA approved or in clinical development. They noticed that the drug ceritinib acts differently than other drugs in its class.
Ceritinib targets a protein called ALK, and is approved to treat patients with ALK-rearranged metastatic non-small cell lung cancer. Their research found that ceritinib also inhibits the growth of lung cancer cells that do not have genetic alterations in the ALK gene.
After an extensive set of experiments to learn how ceritinib worked in cells without ALK rearrangements, they discovered the drug inhibits several other previously unknown targets, and that these signals converge onto a protein known to be responsible for causing drug resistance to paclitaxel.
Importantly, the researchers showed that ceritinib combined with paclitaxel was more effective than either agent alone at reducing cell viability.
These findings suggest that ceritinib together with paclitaxel may be effective against other cancers that do not have ALK rearrangements, and that this drug combination may be used to target a network of changes in cancer.
"The results also demonstrate the benefits of using a combined screening, proteomics and computer-based modeling approach to identify drugs that act on multiple targets and to determine how they function," said study lead author Uwe Rix, Ph.D., assistant member of the Drug Discovery Program at Moffitt.
"In the future, this strategy may facilitate further drug repurposing efforts and lead to an increase in new therapy options for patients with difficult-to-treat diseases."
Source: Eurekalert
Oral Drug Protects Healthy Tissue From Radiation In Non-Small Lung Cancer
An experimental oral drug has been shown to protect healthy tissue from radiation effect in patients suffering from advanced non-small cell lung cancer.
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Cancer News
The approvals of pipeline drugs such as momelotinib and Vonjo for myelofibrosis (a rare type of blood cancer) over some time will handle the critical unmet needs.
New study highlights the dual role that blood vessels can play in cancer immunotherapy and eliciting anti-tumor immune responses or even preventing breast cancer spread.
New study evaluated the association between exposure to the chemical agent orange and the development of blood cancer with increased bleeding and blood clot formation.
Study suggests two-year immunotherapy treatment for advanced lung cancer may be reasonable
A ray of hope for glioma patients as targeted therapy boosts treatment duration.